CLPBF (Coloplast AS) Valuation Rank


CLPBF Coloplast AS CLPBF
72 GF Score
Price $57.41
GF Value $125.62
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is Coloplast AS Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Coloplast AS Valuation Rank Related Terms

CLPBF
72GF Score
Coloplast AS CLPBF
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Coloplast AS (CLPBF) Overvalued in 2026?

Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued. The current stock price of $57.41 is trading 54.3% below its estimated GF Value™ of $125.62. GuruFocus considers Coloplast AS to be Significantly Undervalued.

Key valuation signals for CLPBF:

  • Valuation Rank:
  • GF Value™: $125.62 vs. price of $57.41 (54.3% below fair value)
  • GF Score™: 72/100 with 7 warning signs

No single metric tells the full story. See the CLPBF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coloplast AS Business Description

Address Holtedam 1-3, Humlebaek, DNK, DK-3050
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
72GF Score

Get the complete analysis for CLPBF

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$57.41
Price
$125.62
GF Value